- NGM Biopharmaceuticals, Inc. chosen as recipient
- Grant program provides tools and support to help advance lifesaving drugs to market
EMD Millipore, the Life Science division of Merck KGaA, Darmstadt, Germany, announced today that NGM Biopharmaceuticals, Inc. is the recipient of its 2014 Emerging Biotech Grant Program.
Committed to helping advance lifesaving drugs to market, EMD Millipore hosted its first emerging biotech grant program in which the winner receives products and services from EMD Millipore to help develop their molecule. Over 300 entries were accepted from September 3 through November 30, 2014.
The winning entry was selected based on objective criteria of equal weight: (i) the scientific and societal merit of the therapy being developed, and (ii) process challenges and expertise gaps associated with the development of the therapy.
The 2014 grant recipient, NGM Biopharmaceuticals, Inc., is an innovative drug discovery company located in San Francisco, California. NGM is engaged in identifying and developing biologics for the treatment of cardio-metabolic conditions, bile acid-related disease, and potentially other diseases resulting from manifestations of cardio-metabolic abnormalities and metabolic-related cancers.
For more information please visit: www.ebgrant.com and www.emdmillipore.com.